Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 9, 2011, Pages 2092-2098

  Wyen, Christoph ^a   Hendra, Heidy ^a   Siccardi, Marco ^b   Platten, Martin ^a   Jaeger, Hans ^c   Harrer, Thomas ^d   Esser, Stefan ^e   Bogner, Johannes R ^f   Brockmeyer, Norbert H ^g   Bieniek, Bernhard ^h   Rockstroh, Juergen ⁱ   Hoffmann, Christian ^j   Stoehr, Albrecht ^k   Michalik, Claudia ^l   Dlugay, Verena ^m   Jetter, Alexander ⁿ   Knechten, Heribert ^o   Klinker, Hartwig ^p   Skaletz Rorowski, Adriane ^g   Fätkenheuer, Gerd ^a   Egan, Deirdre ^b   Back, David J ^b   Owen, Andrew ^b   more..

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c HIV Research and Clinical Care Centre Munich   (Germany)

^d UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^e UNIVERSITY OF DUISBURG ESSEN   (Germany)

^f UNIVERSITY OF MUNICH   (Germany)

^g RUHR UNIVERSITY BOCHUM   (Germany)

^h PraxisCityOst   (Germany)

ⁱ UNIVERSITY OF BONN   (Germany)

^j UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^k Institute for Interdisciplinary Medicine   (Germany)

^l UNIVERSITY OF COLOGNE   (Germany)

^m UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

ⁿ UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^o Praxen Zentrum Blondelstrasse   (Germany)

^p UNIVERSITY OF WÜRZBURG   (Germany)

more..

Author keywords

Drug disposition; Metabolism; Pharmacogenetics; Pharmacokinetics

Indexed keywords

CONSTITUTIVE ANDROSTANE RECEPTOR; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; GLUCURONOSYLTRANSFERASE 2B7; LAMIVUDINE PLUS ZIDOVUDINE; PREGNANE X RECEPTOR; ZIDOVUDINE;

ADULT; ARTICLE; CAUCASIAN; CENTRAL NERVOUS SYSTEM DISEASE; CONTROLLED STUDY; DEMOGRAPHY; DEPRESSION; DRUG WITHDRAWAL; ETHNIC DIFFERENCE; FEMALE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEGRO; PHARMACOGENETICS; RISK FACTOR; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ARYL HYDROCARBON HYDROXYLASES; BENZOXAZINES; COHORT STUDIES; DNA; ETHNIC GROUPS; FEMALE; GENOTYPE; GERMANY; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; OXIDOREDUCTASES, N-DEMETHYLATING; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RISK FACTORS; SEX CHARACTERISTICS; SMOKING; SOCIOECONOMIC FACTORS;

EID: 80051685348     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr272     Document Type: Article

References (40)

1. Fumaz CR, Tuldra A, Ferrer MJ et al. Quality of life, emotional status, and adherence of HIV-1-infected patients treated with efavirenz versus protease inhibitor-containing regimens. J Acquir Immune Defic Syndr 2002; 29: 244-53.
2. Hawkins T, Geist C, Young B et al. Comparison of neuropsychiatric side effects in an observational cohort of efavirenz- and protease inhibitor-treated patients. HIV Clin Trials 2005; 6: 187-96.
3. Perez-Molina JA. Safety and tolerance of efavirenz in different antiretroviral regimens: results from a national multicenter prospective study in 1,033 HIV-infected patients. HIV Clin Trials 2002; 3: 279-86.
4. Fumaz CR, Munoz-Moreno JA, Molto J et al. Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence. J Acquir Immune Defic Syndr 2005; 38: 560-5.
5. Manfredi R, Calza L, Chiodo F. Efavirenz versus nevirapine in current clinical practice: a prospective, open-label observational study. J Acquir Immune Defic Syndr 2004; 35: 492-502.
6. Sabbatani S, Fulgaro C, Rosticelli E. [Efficacy of efavirenz in a mixed population of patients. Identification of drop-out causes]. Infez Med 2002; 10: 163-8.
7. Spire B, Carrieri P, Garzot MA et al. Factors associated with efavirenz discontinuation in a large community-based sample of patients. AIDS Care 2004; 16: 558-64.
8. Nunez M, Gonzalez de Requena D, Gallego L et al. Higher efavirenz plasma levels correlate with development of insomnia. J Acquir Immune Defic Syndr 2001; 28: 399-400.
9. Clifford DB, Evans S, Yang Y et al. Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann Intern Med 2005; 143: 714-21.
10. Gallego L, Barreiro P, del Rio R et al. Analyzing sleep abnormalities in HIV-infected patients treated with efavirenz. Clin Infect Dis 2004; 38: 430-2.
11. Lang T, Klein K, Fischer J et al. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 2001; 11: 399-415.
12. Haas DW, Bartlett JA, Andersen JW et al. Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration. Clin Infect Dis 2006; 43: 783-6.
13. Haas DW, Ribaudo HJ, Kim RB et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 2004; 18: 2391-400.
14. Ribaudo HJ, Haas DW, Tierney C et al. Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group study. Clin Infect Dis 2006; 42: 401-7.
15. Ritchie MD, Haas DW, Motsinger AA et al. Drug transporter and metabolizing enzyme gene variants and nonnucleoside reversetranscriptase inhibitor hepatotoxicity. Clin Infect Dis 2006; 43: 779-82.
16. Rodriguez-Novoa S, Barreiro P, Rendon A et al. Influence of 516G.T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects. Clin Infect Dis 2005; 40: 1358-61.
17. Rotger M, Colombo S, Furrer H et al. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genomics 2005; 15: 1-5.
18. Tsuchiya K, Gatanaga H, Tachikawa N et al. Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. Biochem Biophys Res Commun 2004; 319: 1322-6.
19. Wyen C, Hendra H, Vogel M et al. Impact of CYP2B6 983T.C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. J Antimicrob Chemother 2008; 61: 914-8.
20. Kwara A, Lartey M, Sagoe KW et al. CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients. AIDS 2009; 23: 2101-6.
21. Kwara A, Lartey M, Sagoe KW et al. CYP2B6 (c.516G→T) and CYP2A6 (*9B and/or*17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients. Br J Clin Pharmacol 2009; 67: 427-36.
22. di Iulio J, Fayet A, Arab-Alameddine M et al. In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. Pharmacogenet Genomics 2009; 19: 300-9.
23. Arab-Alameddine M, Di Iulio J, Buclin T et al. Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals. Clin Pharmacol Ther 2009; 85: 485-94.
24. Belanger AS, Caron P, Harvey M et al. Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine. Drug Metab Dispos 2009; 37: 1793-6.
25. Chang TK, Bandiera SM, Chen J. Constitutive androstane receptor and pregnane X receptor gene expression in human liver: interindividual variability and correlation with CYP2B6 mRNA levels. Drug Metab Dispos 2003; 31: 7-10.
26. Wortham M, Czerwinski M, He L et al. Expression of constitutive androstane receptor, hepatic nuclear factor 4 a, and P450 oxidoreductase genes determines interindividual variability in basal expression and activity of a broad scope of xenobiotic metabolism genes in the human liver. Drug Metab Dispos 2007; 35: 1700-10.
27. Shelby MK, Klaassen CD. Induction of rat UDP-glucuronosyltransferases in liver and duodenum by microsomal enzyme inducers that activate various transcriptional pathways. Drug Metab Dispos 2006; 34: 1772-8.
28. Lamba J, Lamba V, Strom S et al. Novel single nucleotide polymorphisms in the promoter and intron 1 of human pregnane X receptor/NR1I2 and their association with CYP3A4 expression. Drug Metab Dispos 2008; 36: 169-81.
29. Jinno H, Tanaka-Kagawa T, Hanioka N et al. Identification of novel alternative splice variants of human constitutive androstane receptor and characterization of their expression in the liver. Mol Pharmacol 2004; 65: 496-502.
30. Siccardi M, D'Avolio A, Baietto L et al. Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C→T) with reduced concentrations of unboosted atazanavir. Clin Infect Dis 2008; 47: 1222-5.
31. Cortes C, Chaikan A, Owen A et al. Correlates of efavirenz exposure in HIV infected patients from Chile reveals novel associations with a polymorphism in the constitutive androstane receptor and smoking. In: Abstracts of the Tenth International Workshop on Clinical Pharmacology of HIV Therapy, Amsterdam, Netherlands 2009. Abstract P-04. Rev Antivir Ther 2009; Suppl.
32. Jansen K, Michalik C, Hahn M et al. The patient cohort of the German Competence Network for HIV/AIDS (KompNet): a profile. Eur J Med Res 2009; 14: 323-31.
33. Ribaudo HJ, Liu H, SchwabM et al. Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study. J Infect Dis 2010; 202: 717-22.
34. Stohr W, Back D, Dunn D et al. Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication. Antivir Ther 2008; 13: 675-85.
35. Schackman BR, Ribaudo HJ, Krambrink A et al. Racial differences in virologic failure associated with adherence and quality of life on efavirenz-containing regimens for initial HIV therapy: results of ACTG A5095. J Acquir Immune Defic Syndr 2007; 46: 547-54.
36. Lamba V, Yasuda K, Lamba JK et al. PXR (NR1I2): splice variants in human tissues, including brain, and identification of neurosteroids and nicotine as PXR activators. Toxicol Appl Pharmacol 2004; 199: 251-65.
37. Washio I, Maeda M, Sugiura C et al. Cigarette smoke extract induces CYP2B6 through constitutive androstane receptor in hepatocytes. Drug Metab Dispos 2011; 39: 1-3.
38. Yamazaki H, Inoue K, Hashimoto M et al. Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol 1999; 73: 65-70.
39. Hawkins BT, Abbruscato TJ, Egleton RD et al. Nicotine increases in vivo blood-brain barrier permeability and alters cerebral microvascular tight junction protein distribution. Brain Res 2004; 1027: 48-58.
40. Lockman PR, Van der Schyf CJ, Abbruscato TJ et al. Chronic nicotine exposure alters blood-brain barrier permeability and diminishes brain uptake of methyllycaconitine. J Neurochem 2005; 94: 37-44